European Antidepressants Markets : Market Research Report

European Antidepressants Markets

Published: Jun. 22, 2006 - 100 Pages

1. Executive Summary
        1. Introduction to the European Antidepressants Market
                  1. Summary of the European Antidepressants Market

2. Glossary of Terms and Research Methodology
        1. List of Terms
                  1. Abbreviations
        2. Research Methodology
                  1. Methodology of Research for the European Antidepressants Market

3. Industry Challenges
        1. Challenges and Issues
                  1. Challenges Facing the European Antidepressants Market

4. Market Engineering Research of the European Antidepressants Market
        1. Forecasts of the Overall Market
                  1. Overview of Depression and Related Disorders
                  2. Disease Burden
                  3. Disease Prevalence
                  4. Market Engineering Measurements
                  5. Factors Driving the European Antidepressants Market
                  6. Factors Restraining the European Antidepressants Market
                  7. Revenue Forecasts
                  8. Trends by Geography
                  9. Trends by Segment
                  10. Competitive Structure
                  11. Market Share Analysis

5. Segment-wise Forecasts
        1. Forecasts of the Selective Serotonin Reuptake Inhibitor (SSRI) Market
                  1. Introduction to SSRIs
                  2. Market Engineering Measurements
                  3. Revenue Forecasts
        2. Forecasts of the Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Market
                  1. Introduction to SNRIs
                  2. Market Engineering Measurements
                  3. Revenue Forecasts
        3. Forecasts of the Other Antidepressant Market
                  1. Introduction to Other Antidepressants
                  2. Market Engineering Measurements
                  3. Revenue Forecasts

6. Opportunities by Geography
        1. The United Kingdom Antidepressants Market
                  1. Market Overview
                  2. Trends and Issues
        2. The German Antidepressants Market
                  1. Market Overview
                  2. Trends and Issues
        3. The French Antidepressants Market
                  1. Market Overview
                  2. Trends and Issues
        4. The Spanish Antidepressants Market
                  1. Market Overview
                  2. Trends and Issues
        5. The Italian Antidepressants Market
                  1. Market Overview
                  2. Trends and Issues
        6. The Benelux Antidepressants Market
                  1. Market Overview
                  2. Trends and Issues
        7. The Scandinavian Antidepressants Market
                  1. Market Overview
                  2. Trends and Issues

7. Product Analysis
        1. Analysis of Key Antidepressants in the European Market
                  1. Prozac
                  2. Zoloft
                  3. Paxil
                  4. Citalopram
                  5. Cipralex
                  6. Wellbutrin
                  7. Effexor
        2. Analysis of Potential Blockbuster Antidepressants
                  1. Cymbalta
                  2. Saredutant
                  3. DVS-233

8. Antidepressant Pipeline Analysis
        1. Antidepressants in the Pipeline
                  1. Glaxosmithkline
                  2. Lundbeck
                  3. Sanofi-Aventis
                  4. Astrazeneca
                  5. Wyeth

9. Strategic Recommendations
        1. Recommendations for the European Antidepressant Market Participants
                  1. Strategies for the European Antidepressants Market

10. Frost & Sullivan Awards for the Antidepressants Market
        1. Frost & Sullivan Awards
                  1. Frost & Sullivan Awards
                  2. Product Differentiation Innovation Award
                  3. Growth Strategy Leadership Award

11. Database of Key Industry Participants (DKIP)
        1. List of Key Industry Participants
                  1. Database of Key Market Participants

12. Decision Support Databases (DSDs)
        1. DSD Tables
                  1. Number of Psychiatry Beds
                  2. Prevalence of Urinary Incontinence

List of Figures

Chapter 3

Antidepressants Market: Impact of Top Industry Challenges (Europe), 2006-2012

Chapter 4

Antidepressants Market: Market Drivers Ranked in Order of Impact (Europe), 2006-2012

Antidepressants Market: Market Restraints Ranked in Order of Impact (Europe), 2006-2012

Antidepressants Market: Revenue Forecasts (Europe), 2002-2012

Antidepressants Market: Per Cent of Revenues by Geographic Region (Europe), 2005

Antidepressants Market: Per Cent of Revenues by Segment (Europe), 2002-2012

Antidepressants Market: Competitive Structure (Europe), 2005

Antidepressants Market: Market Share and Growth Rate of Leading Products (Europe), 2005

Chapter 5

Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Revenue Forecasts (Europe), 2002-2012

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Market: Revenue Forecasts (Europe), 2002-2012

Other Antidepressants Market: Revenue Forecasts (Europe), 2002-2012

Chapter 12

Decision Support Database: Number of Beds in Psychiatric Hospitals in '000 (World), 1999-2006

Decision Support Database: Prevalence of Urinary Incontinence in Million (World), 1999-2006

Abstract

Research Overview

This Frost & Sullivan research service titled European Antidepressants Markets provides a detailed analysis of the antidepressants markets, with a description of key market drivers and restraints. An analysis of the product pipelines of leading companies as well as overall market forecasts are also provided. In this research, Frost & Sullivan’s expert analysts thoroughly examine the following markets: selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other antidepressants.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

Selective serotonin reuptake inhibitors (SSRIs)
Serotonin-norepinephrine reuptake inhibitors (SNRIs)
Other antidepressants

Market Overview

Better Efficacy and Relatively Lesser Side-effects of SNRIs to Promote Continued Market Growth

The increasing incidence of depression and anxiety disorders in Europe is leading to greater focus on diagnosis and treatment options, thus contributing to the significance of antidepressants. Apart from this, antidepressants are being investigated for their utility in a number of central nervous system (CNS) disorders. As several antidepressants are also being prescribed off-label for a variety of disorders, such as phobias and menopause-related symptoms, among others, continued market developments are expected. Currently, growth in the market is strongly led by the performance of serotonin-norepinephrine reuptake inhibitors (SNRIs), a class of drugs that features limited generic competition and recently introduced brands. Besides, there are a small number of brands outside the selective serotonin reuptake inhibitors (SSRI) and SNRI classes of drugs that are augmenting overall market sales.

"In the future, growth in the market is expected to be driven primarily by SNRIs as well as other new classes of antidepressants," says Sumanth Kambhammettu, the analyst of this research service. "This can be attributed to the prevailing perception of greater efficacy and reduced side-effects of SNRIs in comparison to the SSRI class of drugs." Increasing evidence linking SSRIs to instances of suicide among children and adolescents is also hampering the performance of this segment. Moreover, escalating generic competition is anticipated to result in increased market share of SNRIs and other novel antidepressants, thereby affecting the growth of the SSRI class of drugs that currently dominate the market.

Effective Product Life-cycle Management Crucial to Combat Intensifying Competition

"The maturity of the market, along with increasing parallel importation, reference pricing and rising generic competition are likely to hinder market progress," remarks Mr. Kambhammettu. "In view of surging healthcare costs, most of the European nations have implemented stringent cost -containing measures, resulting in intensifying pressure on profits." Moreover, the implementation of regulatory standards such as the decentralisation of reimbursement policies in Italy and the reimbursement restrictions on certain drugs enforced by majority of the governments in Europe are crucial restraints.

Despite these challenges, the high level of unmet clinical needs and the presence of limited innovative drugs, combined with the potential for blockbuster products will continue to drive market expansion. Product life-cycle management will gain prominence and market participants will need to focus on strategically positioning their products early in the life cycle to generate maximum revenues in the patent exclusivity period. Furthermore, research will need to emphasise the expansion of product indications and prolong the life cycles of blockbuster molecules. Establishing marketing collaborations to implement aggressive marketing and product promotion will also become essential to gain a competitive edge in the market.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

advertise with us

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

European Antidepressants Markets

Table of Contents

Abstract